GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), liraglutide, and tirzepatide (Mounjaro) have gained widespread popularity for their effectiveness in helping people lose weight and manage blood sugar levels
Injection-Based Administration Subcutaneous injections: All GLP-1 RAs are administered via subcutaneous injection Prefilled pens: Most common delivery system, allows for self-administration Auto-injectors: Simplify the process for patients with dexterity issues Multi-dose pens: Require dose dialing and needle attachment Dosing frequency: Daily: Liraglutide (Saxenda, Victoza), some formulations of exenatide (Byetta) Weekly: Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), exenatide extended-release (Bydureon) Titration schedules: Most FDA-approved GLP-1 RAs require gradual dose escalation to minimize gastrointestinal side effects
NAD+ Injection Kit 350.00 or subscribe to save up to 20% Discover our NAD+ AT Home Injection Kit the UKs first for at home NAD+ Injections
What did the FDA change about TRT cardiovascular safety in 2025
The medication works to slow the transit of the food in the intestinal tract, creating a feeling of fullness for longer than usual
The goal of current research is to understand these pathways well enough to keep the satiety benefits without losing the ability to enjoy life
